← back to search

Christina Gavegnano

Harvard University · US
🔎 Find collaborators in Virology · Infectious Diseases →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV-related health complications and treatments, and HIV/AIDS Research and Interventions.
h-index
20
citations
1,459
works
47
NIH funding
primary concept
email

Recent publications

Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections
Frontiers in Immunology 2022cited by 20position: lastdoi
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus
Clinical Infectious Diseases 2021cited by 59position: middledoi
The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency
Frontiers in Immunology 2021cited by 31position: middledoi
Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators
Frontiers in Immunology 2021cited by 24position: lastdoi
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Clinical Infectious Diseases 2020cited by 141position: middledoi
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
Journal of the American Heart Association 2020cited by 56position: middledoi
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro
Journal of Neuroinflammation 2019cited by 63position: firstdoi
Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network
Antiviral Research 2017cited by 132position: middledoi
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
PLoS Pathogens 2017cited by 100position: firstdoi
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model
Neurobiology of Disease 2016cited by 84position: middledoi
Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation <i>In Vitro</i>
Antimicrobial Agents and Chemotherapy 2014cited by 103position: firstdoi
Antiretroviral Monocyte Efficacy Score Linked to Cognitive Impairment in Hiv
Antiviral Therapy 2012cited by 73position: middledoi
Cellular Pharmacology and Potency of HIV-1 Nucleoside Analogs in Primary Human Macrophages
Antimicrobial Agents and Chemotherapy 2012cited by 35position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Raymond F. Schinazi · Emory University10 papers (2012–2021)Selwyn J. Hurwitz · Emory University5 papers (2012–2021)Vincent C. Marconi · Emory University4 papers (2017–2021)Susan Pereira Ribeiro · Emory Healthcare2 papers (2017–2022)Rafick‐Pierre Sékaly · Emory Healthcare2 papers (2017–2021)Woldeab B. Haile · Atlanta Medical Center2 papers (2016–2019)William R. Tyor · Emory University2 papers (2016–2019)Mervi Detorio · Centers for Disease Control and Prevention2 papers (2012–2014)Deanna A. Kulpa · Emory University2 papers (2017–2022)Sijia Tao · Emory University2 papers (2016–2019)Boghuma K Titanji · Emory University2 papers (2020–2020)Yong Jiang · Shanghai University2 papers (2016–2019)Colin Song · Fiona Stanley Hospital2 papers (2021–2022)Monica D. Reece · Emory University2 papers (2021–2022)Edgar T. Overton · AIDS Clinical Trials Group1 papers (2021–2021)Stephanie Santos · Boston Medical Center1 papers (2017–2017)Charles Flexner · Johns Hopkins Medicine1 papers (2021–2021)Thomas W. North · Emory University1 papers (2012–2012)Aarthi Talla · University of Phoenix1 papers (2017–2017)Abeer Moanna · World Wide Web Consortium1 papers (2020–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Virology · Infectious Diseases →